KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Approved in Japan for Patients With Unresectable, Advanced or Recurrent Endometrial Carcinoma That Progressed After Cancer Chemotherapy
Go back to KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Approved in Japan for Patients With Unresectable, Advanced or Recurrent Endometrial Carcinoma That Progressed After Cancer Chemotherapy| Merck & Co. (NYSE: MRK) | Delayed: 129.56 +4.19 (3.34%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $125.37 | 52 Week High | $65.46 | |||
| Open | $126.18 | 52 Week Low | $47.97 | |||
| Day High | $129.61 | P/E | 88.14 | |||
| Day Low | $125.99 | EPS | $1.47 | |||
| Volume | 7,833,992 | |||||
